1. Home
  2. BEAM vs SPNS Comparison

BEAM vs SPNS Comparison

Compare BEAM & SPNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • SPNS
  • Stock Information
  • Founded
  • BEAM 2017
  • SPNS 1982
  • Country
  • BEAM United States
  • SPNS Israel
  • Employees
  • BEAM N/A
  • SPNS N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • SPNS Computer Software: Prepackaged Software
  • Sector
  • BEAM Health Care
  • SPNS Technology
  • Exchange
  • BEAM Nasdaq
  • SPNS Nasdaq
  • Market Cap
  • BEAM 1.6B
  • SPNS 1.6B
  • IPO Year
  • BEAM 2020
  • SPNS 1992
  • Fundamental
  • Price
  • BEAM $20.01
  • SPNS $30.09
  • Analyst Decision
  • BEAM Strong Buy
  • SPNS Buy
  • Analyst Count
  • BEAM 11
  • SPNS 4
  • Target Price
  • BEAM $48.90
  • SPNS $34.25
  • AVG Volume (30 Days)
  • BEAM 2.0M
  • SPNS 158.6K
  • Earning Date
  • BEAM 08-05-2025
  • SPNS 07-31-2025
  • Dividend Yield
  • BEAM N/A
  • SPNS 1.99%
  • EPS Growth
  • BEAM N/A
  • SPNS 11.11
  • EPS
  • BEAM N/A
  • SPNS 1.30
  • Revenue
  • BEAM $63,578,000.00
  • SPNS $544,235,000.00
  • Revenue This Year
  • BEAM N/A
  • SPNS $8.30
  • Revenue Next Year
  • BEAM $8.82
  • SPNS $7.42
  • P/E Ratio
  • BEAM N/A
  • SPNS $23.15
  • Revenue Growth
  • BEAM N/A
  • SPNS 3.84
  • 52 Week Low
  • BEAM $13.53
  • SPNS $23.69
  • 52 Week High
  • BEAM $35.25
  • SPNS $41.22
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 68.31
  • SPNS 64.37
  • Support Level
  • BEAM $16.59
  • SPNS $28.44
  • Resistance Level
  • BEAM $17.38
  • SPNS $29.56
  • Average True Range (ATR)
  • BEAM 1.10
  • SPNS 0.51
  • MACD
  • BEAM 0.35
  • SPNS 0.09
  • Stochastic Oscillator
  • BEAM 89.70
  • SPNS 94.98

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About SPNS Sapiens International Corporation N.V. (Cayman Islands)

Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.

Share on Social Networks: